Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEGIN: Telaglenastat in NF1, KEAP1/NRF2, and LKB1 Aberrant Tumors
NCT03872427Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telaglenastat in solid tumor and malignant peripheral nerve sheath tumor (MPNST), sponsored by National Cancer Institute. Primary endpoint: Best Overall Response Rate at 6 months. Started Dec 2019; status: active, not recruiting.
02
Drugs
telaglenastat
03
Conditions
solid tumormalignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT03872427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872427.